SCHEMBL6498960

SCHEMBL6498960

CCOC(=O)Cc1c(O)nc2ccccc2c1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.50
TOP2A P11388 2/20 0.50
TSHR P16473 2/20 0.50
USP2 O75604 1/20 0.50
MAPK1 P28482 1/20 0.50
TRPM8 Q7Z2W7 1/20 0.49
POLB P06746 3/20 0.48
KDM4E B2RXH2 3/20 0.48
GLA P06280 1/20 0.48
PRNP P04156 4/20 0.47
RXFP1 Q9HBX9 3/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2C9 P11712 2/20 0.47
CYP2C19 P33261 2/20 0.47
ABCB1 P08183 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
ELANE P08246 2/20 0.46
MAPT P10636 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12955949 0.89 HSD17B10 (0.53) HSD17B10TOP2ATSHRUSP2MAPK1
SCHEMBL6491480 0.84 LMNA (0.51) HSD17B10TSHRUSP2MAPK1TRPM8
SCHEMBL6499213 0.82 HSD17B10 (0.44) HSD17B10KDM4EMAPTTDP1L3MBTL1
SCHEMBL6499160 0.81 HSD17B10 (0.44) HSD17B10TSHRUSP2MAPK1TRPM8
SCHEMBL11775553 0.81 KDM4E (0.51) HSD17B10POLBKDM4EGLAMAPT
SCHEMBL6492344 0.79 HSD17B10 (0.42) HSD17B10TSHRUSP2MAPK1TRPM8
SCHEMBL15800529 0.79 HSD17B10 (0.54) HSD17B10TOP2ATSHRUSP2MAPK1
SCHEMBL16624740 0.78 ALDH1A1 (0.49) HSD17B10TSHRUSP2MAPK1TRPM8
SCHEMBL6500221 0.77 ABCB1 (0.50) MAPK1POLBRXFP1ABCB1MAPT
SCHEMBL29860485 0.77 SMN1; SMN2 (0.58) POLBKDM4EGLANPSR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6908932-B2 Cancer therapy ICONIX PHARMACEUTICALS, INC. (US) 2005-06-21 US disclosed
US-20030149074-A1 Modulators of phosphoinositide 3-kinase ENTELOS HOLDING CORP. 2003-08-07 US disclosed
WO-2003035618-A2 MODULATORS OF PHOSPHOINOSITIDE 3-KINASE ICONIX PHARMACEUTICALS, INC. (US) 2003-05-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149074-A1 Modulators of phosphoinositide 3-kinase PIK3R1, PIK3R3, PIK3R4 HSD17B10 894/4885TOP2A 3052/4885TSHR 735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.